Oncology and Advanced Solid Tumors
Relay Therapeutics Inc. supports clinical research in advanced solid tumors with a focus on cancers driven by PIK3CA alterations, including disease settings where the mutation is identified in blood and/or tumor tissue.
- PIK3CA-mutant cancer
- Metastatic breast cancer
- Hormone receptor positive, HER2-negative disease
The sponsor’s oncology portfolio centers on targeted treatment approaches for molecularly defined breast cancer and other solid malignancies.
Breast Cancer and Hormone Receptor–Positive Disease
Clinical research activity includes PIK3CA-mutant, HR+/HER2- locally advanced and metastatic breast cancer, reflecting interest in tumors with specific signaling pathway alterations.
- Locally advanced breast cancer
- Metastatic breast cancer
- PIK3CA-driven breast tumors
These studies address treatment needs in breast cancer populations defined by PIK3CA mutation status and receptor subtype.
PIK3CA-Related Overgrowth Spectrum and Malformations
Relay Therapeutics Inc. also funds research in PIK3CA Related Overgrowth Spectrum and PIK3CA-driven malformations, extending its therapeutic interest beyond oncology into rare genetic overgrowth disorders.
- PIK3CA-related overgrowth spectrum
- Congenital malformations
- Pathology driven by PIK3CA mutation
This area reflects activity in conditions where aberrant PIK3CA signaling contributes to abnormal tissue growth and developmental anomalies.
Targeted Molecular Therapy
The sponsor’s clinical research landscape is shaped by investigation of therapies directed at PIK3CA-mutated disease biology, including combinations used in advanced breast cancer and other solid tumors.
- PI3K pathway targeting
- Mutation-selected treatment
- Solid tumor precision medicine
Its funded trials span molecularly selected cancers and rare non-malignant disorders linked to the same pathway.
